Creative Planning Has $1.90 Million Stock Holdings in Glaukos Corporation $GKOS

Creative Planning raised its stake in Glaukos Corporation (NYSE:GKOS) by 28.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,368 shares of the medical instruments supplier’s stock after buying an additional 4,105 shares during the period. Creative Planning’s holdings in Glaukos were worth $1,897,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Park Place Capital Corp lifted its stake in shares of Glaukos by 68.4% in the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 162 shares during the last quarter. Harbor Capital Advisors Inc. increased its holdings in Glaukos by 0.4% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 39,305 shares of the medical instruments supplier’s stock worth $4,060,000 after purchasing an additional 173 shares in the last quarter. AQR Capital Management LLC raised its position in Glaukos by 2.6% in the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock valued at $766,000 after purchasing an additional 198 shares during the last quarter. Profund Advisors LLC raised its position in Glaukos by 13.9% in the second quarter. Profund Advisors LLC now owns 2,822 shares of the medical instruments supplier’s stock valued at $291,000 after purchasing an additional 345 shares during the last quarter. Finally, Avior Wealth Management LLC boosted its stake in shares of Glaukos by 12.3% during the second quarter. Avior Wealth Management LLC now owns 3,800 shares of the medical instruments supplier’s stock valued at $393,000 after purchasing an additional 416 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Insider Transactions at Glaukos

In other news, CFO Alex R. Thurman sold 315 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $105.00, for a total value of $33,075.00. Following the completion of the sale, the chief financial officer directly owned 50,488 shares in the company, valued at $5,301,240. This trade represents a 0.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, COO Joseph E. Gilliam sold 19,340 shares of the business’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $90.00, for a total value of $1,740,600.00. Following the completion of the sale, the chief operating officer directly owned 92,366 shares of the company’s stock, valued at $8,312,940. The trade was a 17.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 5.80% of the stock is owned by corporate insiders.

Glaukos Stock Performance

Shares of GKOS stock opened at $105.53 on Thursday. The firm has a 50 day moving average of $85.97 and a 200-day moving average of $91.71. The company has a market cap of $6.06 billion, a price-to-earnings ratio of -68.53 and a beta of 0.81. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09. Glaukos Corporation has a 52 week low of $73.16 and a 52 week high of $163.71.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.11. The business had revenue of $133.54 million for the quarter, compared to analyst estimates of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.53%. Glaukos’s revenue was up 38.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.28) earnings per share. Glaukos has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GKOS has been the subject of a number of research reports. Wells Fargo & Company raised their price objective on shares of Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. Needham & Company LLC upped their target price on Glaukos from $115.00 to $117.00 and gave the company a “buy” rating in a report on Thursday, October 30th. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a report on Thursday, July 31st. Citigroup upped their price objective on shares of Glaukos from $110.00 to $113.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Finally, Stifel Nicolaus set a $115.00 price objective on shares of Glaukos in a research report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Glaukos currently has a consensus rating of “Moderate Buy” and an average target price of $119.08.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.